Are Dacomitinib/Dacomitinib and Dozerun the same drug?

Dacomitinib/Dacomitinib (Dacomitinib) and Dozerun are actually the same drug, and they only differ in name and market use. Dacomitinib is the international nonproprietary name (INN) of the drug, which is used globally, while Dozerun is the trade name under which it is marketed in China. In other words, the Dozerun that patients see in hospitals or pharmacies is the commercialized version of dacomitinib.

As a second-generation EGFR tyrosine kinase inhibitor, dacomitinib/Dozerun irreversibly binds to the EGFR receptor, blocks its signaling pathway, and inhibits tumor cell proliferation. Compared with the first-generation reversible EGFR inhibitors, dacomitinib has a longer-lasting binding and a relatively slower onset of drug resistance, so it has better application prospects in patients with non-small cell lung cancer with EGFR-sensitive mutations.

Domestically, Pfizer’s original drug Duozerun has been approved for marketing and included in Category B of the National Medical Insurance List, allowing more patients to obtain this innovative drug at a lower economic burden. In overseas markets, people are more accustomed to calling it Dacomitinib. The packaging and specifications of the drug will vary according to the regulations of different countries, but the ingredients and mechanism of action are exactly the same.

It is worth noting that in academic research, clinical guidelines and international exchanges, the generic name "Dacomitinib" is usually used However, when domestic patients use the drug, they will come into contact with the trade name "Dacomitinib" in most cases. This phenomenon is very common in the global drug market. For example, gefitinib is known as Gefitinib internationally, but it is sold under the trade name "Iressa" domestically.

Therefore, it is clear that there is no essential difference between dacomitinib and Dozerun. They are the same drug, and the only difference lies in the naming method. Patients need to pay attention to identification when obtaining information and purchasing drugs to avoid misunderstandings due to differences in names, thereby ensuring correct medication selection and treatment compliance.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro